Wilson Roa1, Lucyna Kepka2, Narendra Kumar2, Valery Sinaika2, Juliana Matiello2, Darejan Lomidze2, Dalenda Hentati2, Douglas Guedes de Castro2, Katarzyna Dyttus-Cebulok2, Suzanne Drodge2, Sunita Ghosh2, Branislav Jeremić2, Eduardo Rosenblatt2, Elena Fidarova2. 1. Wilson Roa, Suzanne Drodge, and Sunita Ghosh, University of Alberta, Alberta Health Services-Cancer Control, Edmonton, Alberta, Canada; Lucyna Kepka, Warmia and Mazury Oncology Center, Olsztyn; Katarzyna Dyttus-Cebulok, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Narendra Kumar, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Valery Sinaika, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; Juliana Matiello, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Douglas Guedes de Castro, Castro DG, AC Camargo Cancer Center, São Paulo, Brazil; Darejan Lomidze, High Technology Medical Center, University Clinic, Tbilisi, Georgia; Dalenda Hentati, Institut National de Cancer Salah Azaiz, Ministère de la Santé Publique, Bab Saadoum, Tunisia; Branislav Jeremić, Institute of Lung Diseases, Institutski put 4, Sremska Kamenica, Serbia; and Eduardo Rosenblatt and Elena Fidarova, International Atomic Energy Agency, Vienna, Austria. wilson.roa@albertahealthservices.ca. 2. Wilson Roa, Suzanne Drodge, and Sunita Ghosh, University of Alberta, Alberta Health Services-Cancer Control, Edmonton, Alberta, Canada; Lucyna Kepka, Warmia and Mazury Oncology Center, Olsztyn; Katarzyna Dyttus-Cebulok, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Narendra Kumar, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Valery Sinaika, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; Juliana Matiello, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Douglas Guedes de Castro, Castro DG, AC Camargo Cancer Center, São Paulo, Brazil; Darejan Lomidze, High Technology Medical Center, University Clinic, Tbilisi, Georgia; Dalenda Hentati, Institut National de Cancer Salah Azaiz, Ministère de la Santé Publique, Bab Saadoum, Tunisia; Branislav Jeremić, Institute of Lung Diseases, Institutski put 4, Sremska Kamenica, Serbia; and Eduardo Rosenblatt and Elena Fidarova, International Atomic Energy Agency, Vienna, Austria.
Abstract
PURPOSE: The optimal radiotherapy regimen for elderly and/or frail patients with newly diagnosed glioblastoma remains to be established. This study compared two radiotherapy regimens on the outcome of these patients. PATIENTS AND METHODS: Between 2010 and 2013, 98 patients (frail = age ≥ 50 years and Karnofsky performance status [KPS] of 50% to 70%; elderly and frail = age ≥ 65 years and KPS of 50% to 70%; elderly = age ≥ 65 years and KPS of 80% to 100%) were prospectively randomly assigned to two arms in a 1:1 ratio, stratified by age (< and ≥ 65 years old), KPS, and extent of surgical resection. Arm 1 received short-course radiotherapy (25 Gy in five daily fractions over 1 week), and arm 2 received commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks). RESULTS: The short-course radiotherapy was noninferior to commonly used radiotherapy. The median overall survival time was 7.9 months (95% CI, 6.3 to 9.6 months) in arm 1 and 6.4 months (95% CI, 5.1 to 7.6 months) in arm 2 (P = .988). Median progression-free survival time was 4.2 months (95% CI, 2.5 to 5.9) in arm 1 and 4.2 months (95% CI, 2.6 to 5.7) in arm B (P = .716). With a median follow-up time of 6.3 months, the quality of life between both arms at 4 weeks after treatment and 8 weeks after treatment was not different. CONCLUSION: There were no differences in overall survival time, progression-free survival time, and quality of life between patients receiving the two radiotherapy regimens. In view of the reduced treatment time, the short 1-week radiotherapy regimen may be recommended as a treatment option for elderly and/or frail patients with newly diagnosed glioblastoma.
RCT Entities:
PURPOSE: The optimal radiotherapy regimen for elderly and/or frail patients with newly diagnosed glioblastoma remains to be established. This study compared two radiotherapy regimens on the outcome of these patients. PATIENTS AND METHODS: Between 2010 and 2013, 98 patients (frail = age ≥ 50 years and Karnofsky performance status [KPS] of 50% to 70%; elderly and frail = age ≥ 65 years and KPS of 50% to 70%; elderly = age ≥ 65 years and KPS of 80% to 100%) were prospectively randomly assigned to two arms in a 1:1 ratio, stratified by age (< and ≥ 65 years old), KPS, and extent of surgical resection. Arm 1 received short-course radiotherapy (25 Gy in five daily fractions over 1 week), and arm 2 received commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks). RESULTS: The short-course radiotherapy was noninferior to commonly used radiotherapy. The median overall survival time was 7.9 months (95% CI, 6.3 to 9.6 months) in arm 1 and 6.4 months (95% CI, 5.1 to 7.6 months) in arm 2 (P = .988). Median progression-free survival time was 4.2 months (95% CI, 2.5 to 5.9) in arm 1 and 4.2 months (95% CI, 2.6 to 5.7) in arm B (P = .716). With a median follow-up time of 6.3 months, the quality of life between both arms at 4 weeks after treatment and 8 weeks after treatment was not different. CONCLUSION: There were no differences in overall survival time, progression-free survival time, and quality of life between patients receiving the two radiotherapy regimens. In view of the reduced treatment time, the short 1-week radiotherapy regimen may be recommended as a treatment option for elderly and/or frail patients with newly diagnosed glioblastoma.
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Marc Zanello; Alexandre Roux; Renata Ursu; Sophie Peeters; Luc Bauchet; Georges Noel; Jacques Guyotat; Pierre-Jean Le Reste; Thierry Faillot; Fabien Litre; Nicolas Desse; Evelyne Emery; Antoine Petit; Johann Peltier; Jimmy Voirin; François Caire; Jean-Luc Barat; Jean-Rodolphe Vignes; Philippe Menei; Olivier Langlois; Edouard Dezamis; Antoine Carpentier; Phong Dam Hieu; Philippe Metellus; Johan Pallud Journal: J Neurooncol Date: 2017-07-19 Impact factor: 4.130